global services
sherpas in blue shirts log

Slow Growth of GICs… Is the Model Losing Its Sheen? | Sherpas in Blue Shirts

The Global In-house Center (GIC, formerly referred to as captives) market was once thriving with unprecedented statistics – 97 new GIC set-ups in 2009, 105 in 2010, and 103 in 2011. Then there was a dip, with only 75 new centers in 2012, and 69 in 2013. This, coupled with numerous acquisitions of GICs by […]

Four Questions You Should Be Asking about Robotics | Sherpas in Blue Shirts

Originally posted on Outsource Magazine Been hanging out under a rock? If so, you may have missed the industry buzz about using “robots” to drive out increased efficiency from manual processes. Definitely a catchy concept (humans truly are annoying) and a potential game-changer. So what do you need to know? I suggest breaking this down […]

Genpact Pharmalink Acquisition Echoes Other Providers’ Efforts to Deepen Life Sciences Expertise | Sherpas in Blue Shirts

On April 23, Genpact announced it had signed an agreement to acquire Pharmalink Consulting, a global provider of regulatory services to the life sciences industry. The move brings Genpact valuable expertise in supporting life sciences research and development functions including regulatory strategy, filing submissions, complex compliance services, and post-licensing activities management. And it well complements […]

Cloud Moves | Sherpas in Blue Shirts

Moving work from an enterprise data center to the cloud is not a lift-and-shift transaction. Cloud moves involve reengineering processes. The good news is that providers are emerging with innovative solutions for deploying to the cloud. We’re watching their progress, as we believe they will disrupt the traditional players in the services market. I blogged […]

Novartis and GSK Restructure to Adjust to the New Normal | Sherpas in Blue Shirts

Novartis on April 22, 2014, announced a succession of deals in a sweeping restructuring. It agreed to buy GlaxoSmithKline’s (GSK) oncology products unit for US$14.5 billion, plus another US$1.5 billion subject to certain milestones. In turn, it divested its vaccines business to GSK for US$7.1 billion, plus royalties. The two companies also announced the creation […]

Page 40 of 121« First...3839404142...Last »